Скачать с ютуб Findings from the HD21 trial: safety profile of the BrECADD regimen in HL в хорошем качестве

Findings from the HD21 trial: safety profile of the BrECADD regimen in HL

Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, summarizes the aims and findings of the HD21 (NCT02661503) trial which compared the safety profile of the novel BrECADD regimen (brentuximab vedotin, etoposide, doxorubicin, cyclophosphamide, dacarbazine, and dexamethasone) to the escalated BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone). Prof. Borchmann explains that BrECADD was found to be superior to BEACOPP in terms of showing improved treatment-related mortality, lower neuropathy, and fewer transfusions. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.